NCT03843905 (METABIOTE) is a clinical trial of no intervention in Colorectal Neoplasms, sponsored by University Hospital, Clermont-Ferrand.

Who is sponsoring NCT03843905?

NCT03843905 is sponsored by University Hospital, Clermont-Ferrand.

What drugs are being tested in NCT03843905?

Interventions in NCT03843905: no intervention.

What condition does NCT03843905 study?

NCT03843905 studies Colorectal Neoplasms, Microbiota, Prognosis, Metabolic Syndrome, Sarcopenia.

Is NCT03843905 still recruiting?

NCT03843905 is currently status unknown. Last updated 18 February 2019.

Last reviewed 2019-02-18 · How we verify

NCT03843905: METABIOTE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.

Status unknown Last updated 18 February 2019

What this trial tests

trial testing no intervention in Colorectal Neoplasms in 300 participants. Status unknown.

Timeline

15 November 2018

Primary endpoint
15 November 2018

15 November 2021

Quick facts

Lead sponsor	University Hospital, Clermont-Ferrand
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	300
Start date	15 November 2018
Primary completion	15 November 2018
Estimated completion	15 November 2021
Sites	1 location across France

Drugs / interventions tested

no intervention

Conditions studied

Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Microbiota — all drugs for Microbiota →
Prognosis — all drugs for Prognosis →
Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

University Hospital, Clermont-Ferrand

Who can join

18 and older, any sex, with Colorectal Neoplasms or Microbiota. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Colorectal cancer (CRC), second leading cause of cancer worldwide, is associated with a poor prognosis, especially in patients with advanced disease. Therefore, there is still a need to develop new prognostic tools to replace or supplement those routinely used, with the aim to optimize treatment strategies. Studies on gut microbiota composition provide new strategies to identify powerful biomarkers. Indeed, beyond its beneficial functions for the host, increasing evidences suggest that gut microbiota is a key factor involved in CRC carcinogenesis. Many clinical studies have described an imbalance in the gut microbiota (dysbiosis) in CRC patients, with the emergence of pathogenic bacterial species, Recent studies reported that pks-positive E. coli, a pathogenic bacterial producing toxin encoded by the pks genomic island, is more frequently detected in CRC patients, suggesting a possible role in tumor development. Therefore, this suggests the potential use of microbial signatures associated with CRC for prognostic assessment. Furthermore, influence of body composition profile (BMI, sarcopenia, metabolic syndrome) also appears to be a new relevant prognostic tool regarding surgical and oncological outcomes following CRC surgery. The aim of this translational research project is to study the impact of these new prognostic tools on surgical and oncologic results in a prospective cohort of patients who underwent CRC surgery at the Digestive Surgery Department of the University Hospital of Clermont-Ferrand (France). This could allow to optimize treatment strategies and provide new ways to identify news promising biomarkers associations in order to better define high risk patients. Investigators aim to identify specific microbial signatures associated with some metabolic profiles in order to improve surgical morbidity and/or response to cancer therapies.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Gut Microbiota as Potential Biomarker and/or Therapeutic Target to Improve the Management of Cancer: Focus on Colibactin-Producing <i>Escherichia coli</i> in Colorectal Cancer.
Veziant J, Villéger R, Barnich N, Bonnet M. · · 2021 · cited 48× · PMID 34063108 · DOI 10.3390/cancers13092215
Prognostic value of a combination of innovative factors (gut microbiota, sarcopenia, obesity, metabolic syndrome) to predict surgical/oncologic outcomes following surgery for sporadic colorectal cancer: a prospective cohort study protocol (METABIOTE).
Veziant J, Poirot K, Chevarin C, Cassagnes L, et al · · 2020 · cited 11× · PMID 31915159 · DOI 10.1136/bmjopen-2019-031472
Crosstalk between metabolic reprogramming and microbiota: implications for cancer progression and novel therapeutic opportunities.
Li X, Jia Y, Li Y, Hei H, et al · · 2025 · cited 2× · PMID 40463381 · DOI 10.3389/fimmu.2025.1582166

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07253506 — Turkish Adaptation, Validity, and Reliability Study of the Patient Experience With Treatment and Self-Management Scale i · not yet recruiting
NCT07253519 — The Relationship Between Mood and Insomnia Severity and Caregiver Burden in Caregivers of Stroke · not yet recruiting
NCT07194096 — Stress Hyperglycemia Ratio and Postoperative Delirium · not yet recruiting
NCT07240337 — Botulinum Toxin Applications in Hemiplegic Patients · recruiting

Other recruiting trials for Colorectal Neoplasms

Currently open trials in the same condition.

NCT06983639 — Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance · NA · recruiting
NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
NCT07239479 — DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy · NA · recruiting
NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
NCT07257653 — The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line · Phase 2 · recruiting

Other University Hospital, Clermont-Ferrand trials

Trials by the same sponsor.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03843905 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
Last refreshed: 18 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03843905.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing